TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15580061

Group type: EXPERIMENTAL
Intervention: 8-week low-cholesterol/low-saturated fat diet (30% total fat, 5% saturated fat, cholesterol <200 mg/daily)
Number of subjects: 35
Study: 11349386

Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Amitriptyline (75 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9209604

Group type: EXPERIMENTAL
Intervention: Amrinone (1.0 mg/kg bolus followed by 10 micrograms/kg/min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dobutamine (5 micrograms/kg/min)
Number of subjects: 20
Study: 7964138

Group type: EXPERIMENTAL
Intervention: Bismuth subgallate (BSG)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Standard operations (Control)
Number of subjects: 202
Study: 3069935

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 31050932

Group type: EXPERIMENTAL
Intervention: Diode laser surgery
Number of subjects: 22

Group type: COMPARATOR
Intervention: Scalpel surgery
Number of subjects: 22
Study: 27798452

Group type: EXPERIMENTAL
Intervention: Modified double-injection group (MDI group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Traditional double-injection group (DI group)
Number of subjects: 90
Study: 26373926

Group type: EXPERIMENTAL
Intervention: Complex intervention including education, decisional support tool, logistical strategies
Number of subjects: 4400

Group type: EXPERIMENTAL
Intervention: Complex intervention
Number of subjects: 4400

Group type: COMPARATOR
Intervention: Usual practice (control)
Number of subjects: 4400
Study: 23352719

Group type: EXPERIMENTAL
Intervention: Early treatment (ET) - laser photocoagulation at high-risk prethreshold ROP
Number of subjects: 401

Group type: COMPARATOR
Intervention: Conventional management (CM) - treatment only if threshold ROP developed
Number of subjects: 401
Study: 21421511

Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg/day
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control (no lipid-lowering drugs)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Pravastatin (both doses)
Number of subjects: 93
Study: 19217695

Group type: EXPERIMENTAL
Intervention: 4% lidocaine cream
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Injected, buffered 1% lidocaine
Number of subjects: 70

Group type: COMPARATOR
Intervention: No local anesthesia
Number of subjects: 70
Study: 17760733

Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg daily for 24 weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 14694502

Group type: EXPERIMENTAL
Intervention: 6 mg betamethasone and lidocaine
Number of subjects: 81

Group type: COMPARATOR
Intervention: 1 ml saline placebo and lidocaine
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: serial steroid injections
Number of subjects: 81
Study: 11601817

Group type: EXPERIMENTAL
Intervention: Aprotinin (200 ml, 2000000 kallikrein inactivator units before the operation and then 50 ml per h until the end of the operation)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 30
Study: 9855026

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7971540

Group type: EXPERIMENTAL
Intervention: Health education programmes for specific diseases (heart disease, diabetes mellitus, bowel diseases) during waiting time; preferred mode of dissemination: leaflets.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inclusion of religious programmes in health education.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Activities during waiting time (reading, sleeping, talking).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Average waiting time.
Number of subjects: 0
Study: 3275750

Group type: EXPERIMENTAL
Intervention: A-COP+ regimen (Adriamycin, vincristine, prednisone, cyclophosphamide, methotrexate, hydrocortisone)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: LSA2-L2 regimen (cyclophosphamide, vincristine, methotrexate, Daunomycin, prednisone, cytarabine, thioguanine, asparaginase, hydroxyurea, carmustine)
Number of subjects: 76

Group type: COMPARATOR
Intervention: A-COP+ regimen
Number of subjects: 76

Group type: COMPARATOR
Intervention: LSA2-L2 regimen
Number of subjects: 76
Study: 31877399

Group type: EXPERIMENTAL
Intervention: Behaviour change interventions using the RANAS approach
Number of subjects: 1945

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 1945
Study: 29243247

Group type: EXPERIMENTAL
Intervention: Designed Breakfast Glucose Profile (DBGP)
Number of subjects: 51

Group type: COMPARATOR
Intervention: 75-g Oral Glucose Tolerance Test (OGTT)
Number of subjects: 51
Study: 27573312

Group type: EXPERIMENTAL
Intervention: Telemedicine follow-up care
Number of subjects: 24

Group type: COMPARATOR
Intervention: Traditional care (Control)
Number of subjects: 24
Study: 24135832

Group type: EXPERIMENTAL
Intervention: Catheter ablation (CA)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Antiarrhythmic drug therapy (ADT)
Number of subjects: 146
Study: 23885611

Group type: EXPERIMENTAL
Intervention: Acupuncture + herb group (group A)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Heparin sodium group (group B)
Number of subjects: 42
Study: 20164324

Group type: EXPERIMENTAL
Intervention: Single-pulse transcranial magnetic stimulation (TMS) applied to the superior temporal sulcus (STS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control location TMS
Number of subjects: 0
Study: 17972087

Group type: EXPERIMENTAL
Intervention: TCu-380A
Number of subjects: 100
Study: 17075823

Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor (TNF) inhibitors (infliximab, etanercept, or adalimumab)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ineligible patients (not receiving TNF inhibitors)
Number of subjects: 100
Study: 12532160

Group type: EXPERIMENTAL
Intervention: MCT diet (67% of treatment fat as MCT oil, 49% octanoate, 50% decanoate)
Number of subjects: 17

Group type: COMPARATOR
Intervention: LCT diet (exclusively beef tallow as treatment fat)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: MCT diet
Number of subjects: 17

Group type: COMPARATOR
Intervention: LCT diet
Number of subjects: 17
Study: 10618543

Group type: EXPERIMENTAL
Intervention: Hexavalent meningococcal outer-membrane-vesicle vaccine (7.5 and 15 microg of individual PorA proteins)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Hexavalent meningococcal outer-membrane-vesicle vaccine
Number of subjects: 337

Group type: COMPARATOR
Intervention: Control group vaccinated against hepatitis B
Number of subjects: 337
Study: 8856250

Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 16
Study: 1512396

Group type: EXPERIMENTAL
Intervention: Well Elderly Program (35 students)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (58 students)
Number of subjects: 93
Study: 6394572

Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg five times a day for five days
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 30071081

Group type: EXPERIMENTAL
Intervention: WORRK tool used to estimate nRTW risk before allocation to vocational pathways
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control group without nRTW risk estimation
Number of subjects: 280
Study: 26460983

Group type: EXPERIMENTAL
Intervention: Dexamethasone (single dose of 0.3 mg/kg)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Prednisolone (1 mg/kg per day for 3 days)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 226

Group type: COMPARATOR
Intervention: Prednisolone
Number of subjects: 226
Study: 24743440

Group type: EXPERIMENTAL
Intervention: Dietary intervention aimed at reducing total fat intake and encouraging increased intake of fruit, vegetables, and grains
Number of subjects: 48835

Group type: EXPERIMENTAL
Intervention: Dietary intervention
Number of subjects: 48835

Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 48835
Study: 23046401

Group type: EXPERIMENTAL
Intervention: Intensive treatment regimen (one‐to‐one education, lifestyle intervention, scheduled clinic visits, strict glucose control, frequent glucose self‐monitoring)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Intensive treatment regimen
Number of subjects: 275
Study: 20057309

Group type: EXPERIMENTAL
Intervention: Intermittent CD4-guided antiretroviral therapy (Drug Conservation group)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Continuous antiretroviral therapy (Viral Suppression group)
Number of subjects: 275
Study: 18555469

Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel (HS)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Electrocautery (EC)
Number of subjects: 32
Study: 15939547

Group type: EXPERIMENTAL
Intervention: Long-term neoadjuvant HT
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Short-term neoadjuvant HT
Number of subjects: 336

Group type: COMPARATOR
Intervention: No neoadjuvant HT
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Pretreatment GU symptoms
Number of subjects: 336
Study: 12668495

Group type: EXPERIMENTAL
Intervention: Atrial high rate episodes (AHREs) detected by pacemaker diagnostics
Number of subjects: 312
Study: 10376615

Group type: EXPERIMENTAL
Intervention: Angiotensin‐converting‐enzyme (ACE) inhibitor
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Beta-blocker
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Calcium‐channel blocker
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Diuretic
Number of subjects: 56
Study: 8910814

Group type: EXPERIMENTAL
Intervention: Hyperglycaemia (20-30 mmol/l)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Euglycaemia (5-10 mmol/l)
Number of subjects: 12
Study: 1799899

Group type: EXPERIMENTAL
Intervention: NTTS/c (20 mg patch at 8.00 am and at 8.00 pm)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: NTTS/a (20 mg patch at 8.00 am and 10 mg at 8.00 pm)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 18
Study: 7046702

Group type: EXPERIMENTAL
Intervention: Superoxide dismutase
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 31076187

Group type: EXPERIMENTAL
Intervention: 8 mg citalopram
Number of subjects: 38

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 38
Study: 29848787

Group type: EXPERIMENTAL
Intervention: 3D laparoscopy
Number of subjects: 75

Group type: COMPARATOR
Intervention: 2D laparoscopy
Number of subjects: 75
Study: 26440810

Group type: EXPERIMENTAL
Intervention: BGStar® blood glucose meter
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: FreeStyle Lite® blood glucose meter
Number of subjects: 110

Group type: COMPARATOR
Intervention: Both meters
Number of subjects: 110
Study: 24690329

Group type: EXPERIMENTAL
Intervention: T‐piece resuscitator
Number of subjects: 1027

Group type: COMPARATOR
Intervention: Self‐inflating bag
Number of subjects: 1027
Study: 22206447

Group type: EXPERIMENTAL
Intervention: Trabecular metal tibial monoblock component (TM)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cemented component
Number of subjects: 70
Study: 20658837

Group type: EXPERIMENTAL
Intervention: Free-choice paradigm (FCP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mathematical theorem
Number of subjects: 0
Study: 17547167

Group type: EXPERIMENTAL
Intervention: Cookstoves (planchas) that vent woodsmoke outdoors through a chimney
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Personal exposure measurements determined by carbon monoxide (CO) passive diffusion tubes
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Kitchen area measurements of PM2.5 mass, PM2.5 levoglucosan, and CO
Number of subjects: 20
Study: 14763548

Group type: EXPERIMENTAL
Intervention: Graftjacket tissue matrix (single administration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study: 12147570

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 11079739

Group type: EXPERIMENTAL
Intervention: IGT/NFG (2-h glucose 7.8-11.0 mmol/l, fasting glucose < 6.1 mmol/l)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: IFG/NGT (fasting glucose 6.1-6.9 mmol/l, 2-h glucose < 7.8 mmol/l)
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: IGT/IFG
Number of subjects: 265

Group type: COMPARATOR
Intervention: NFG/NGT
Number of subjects: 265
Study: 8792507

Group type: EXPERIMENTAL
Intervention: Tests for pyuria and nitrite
Number of subjects: 819

Group type: EXPERIMENTAL
Intervention: Escherichia coli and Staphylococcus saprophyticus
Number of subjects: 819

Group type: EXPERIMENTAL
Intervention: Staphylococcus saprophyticus
Number of subjects: 819

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 819
Study: 1731858

Group type: EXPERIMENTAL
Intervention: High oleic and low erucic acid rapeseed oil diet
Number of subjects: 59

Group type: COMPARATOR
Intervention: Polyunsaturated sunflower oil diet
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 59
Study: 6375803

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (350, 700, and 1400 micrograms)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bisacodyl (1.25, 2.5, and 5 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31635689

Group type: EXPERIMENTAL
Intervention: Intervention plus: bespoke online behaviour change package intervention and personal supplies of moisturising cream for student nurses; optimal availability of moisturising cream for intensive care unit nurses.
Number of subjects: 1956

Group type: COMPARATOR
Intervention: Intervention light: usual care including a dermatitis prevention leaflet.
Number of subjects: 1956

Group type: EXPERIMENTAL
Intervention: Intervention plus for intensive care unit nurses.
Number of subjects: 1956

Group type: EXPERIMENTAL
Intervention: Intervention plus for student nurses.
Number of subjects: 1956
Study: 30312411

Group type: EXPERIMENTAL
Intervention: Coronary computed tomography angiography (CTA)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Conventional angiography
Number of subjects: 223
Study: 26661906

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 1186

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 1186

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 1186

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg/Metformin
Number of subjects: 1186

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg/Metformin
Number of subjects: 1186

Group type: EXPERIMENTAL
Intervention: Predicted ΔHbA1c for canagliflozin/metformin arms
Number of subjects: 1186

Group type: EXPERIMENTAL
Intervention: Predicted ΔHbA1c from new model
Number of subjects: 1186

Group type: EXPERIMENTAL
Intervention: Observed ΔHbA1c from new model
Number of subjects: 1186

Group type: EXPERIMENTAL
Intervention: Predicted ΔHbA1c assuming additivity
Number of subjects: 1186
Study: 24582087

Group type: COMPARATOR
Intervention: Diagnostic model for discriminating UC from HV
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diagnostic model for discriminating UC from CD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model for assessing UC
Number of subjects: 0
Study: 21350803

Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy for advanced gastric cancer
Number of subjects: 10484
Study: 19844183

Group type: EXPERIMENTAL
Intervention: Postexposure Prophylaxis to the Infant (PEPI) with breastfeeding cessation by 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: nevirapine/AZT (NVAZ) with prolonged breastfeeding
Number of subjects: 0
Study: 17561927

Group type: EXPERIMENTAL
Intervention: Soy formula
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Casein hydrolysate
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Rice hydrolysate
Number of subjects: 125

Group type: COMPARATOR
Intervention: Breastfed (non-randomized group)
Number of subjects: 125
Study: 15759025

Group type: EXPERIMENTAL
Intervention: Low-dose combination therapy (CCBs + ARBs)
Number of subjects: 302

Group type: COMPARATOR
Intervention: High-dose CCBs
Number of subjects: 302

Group type: COMPARATOR
Intervention: High-dose ARBs
Number of subjects: 302
Study: 12409683

Group type: EXPERIMENTAL
Intervention: Memantine 20 mg daily
Number of subjects: 579

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 579
Study: 10223241

Group type: EXPERIMENTAL
Intervention: NEO chemoendocrine therapy
Number of subjects: 195

Group type: COMPARATOR
Intervention: ADJ chemoendocrine therapy
Number of subjects: 195
Study: 8830307

Group type: COMPARATOR
Intervention: Botulinum toxin A (2000 U Dysport) alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (2000 U Dysport) with additional repetitive alternating electrical stimulation
Number of subjects: 10
Study: 2195861

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (100 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 31724703

Group type: EXPERIMENTAL
Intervention: CBM group
Number of subjects: 41

Group type: COMPARATOR
Intervention: Memory group
Number of subjects: 41

Group type: COMPARATOR
Intervention: Without AB group
Number of subjects: 41
Study: 30949831

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 84

Group type: COMPARATOR
Intervention: Sedentary group
Number of subjects: 84
Study: 28269769

Group type: EXPERIMENTAL
Intervention: Active Hearing Aids (HAs)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo Hearing Aids (inactive HAs)
Number of subjects: 51
Study: 25621943

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 0.5 mg every 4 weeks
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 8 weeks after 3 monthly doses (2q8)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) as-needed after 3 monthly doses
Number of subjects: 46

Group type: COMPARATOR
Intervention: Laser treatment
Number of subjects: 46
Study: 24101054

Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg, day 1, 21-day cycle) plus erlotinib (150 mg per day)
Number of subjects: 1145

Group type: COMPARATOR
Intervention: Bevacizumab (15 mg/kg, day 1, 21-day cycle) plus placebo
Number of subjects: 1145
Study: 22099189

Group type: EXPERIMENTAL
Intervention: EPO treatment (200 IU/kg•d, 3 times weekly for 2 to 4 weeks)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: EPO treatment
Number of subjects: 70
Study: 19367047

Group type: EXPERIMENTAL
Intervention: Stress inoculation training program (three sessions at four-week intervals) including lectures on responses to stress, coping skills, problem-solving training, group discussions, and self-monitoring.
Number of subjects: 140

Group type: COMPARATOR
Intervention: Waiting list control group (no intervention).
Number of subjects: 140
Study: 16943453

Group type: EXPERIMENTAL
Intervention: Barley crackers (BCr)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Barley cookies (Bc)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Whole-wheat crackers (WWCr)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Whole-wheat cookies (WWc)
Number of subjects: 10
Study: 15313090

Group type: EXPERIMENTAL
Intervention: Special training program using Solutions for Smoking as the main teaching tool
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard training program
Number of subjects: 15
Study: 11776303

Group type: EXPERIMENTAL
Intervention: Warfarin (prescribed between weeks 15-34)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Low molecular weight heparin (s.c. enoxaparin) and low dose aspirin
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 57

Group type: COMPARATOR
Intervention: Low molecular weight heparin and low dose aspirin
Number of subjects: 57
Study: 9231837

Group type: EXPERIMENTAL
Intervention: 2 weeks of intense endurance training
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no change in activity)
Number of subjects: 10
Study: 7956572

Group type: EXPERIMENTAL
Intervention: Continent patients
Number of subjects: 17

Group type: COMPARATOR
Intervention: Incontinent patients
Number of subjects: 17
Study: 3300537

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (general recommendation)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (urine concentration)
Number of subjects: 32
Study: 29322401

Group type: EXPERIMENTAL
Intervention: 50 mg/day mirabegron
Number of subjects: 159
Study: 27330719

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 112

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 112
Study: 24239431

Group type: EXPERIMENTAL
Intervention: Bupropion-SR 150 mg
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 22025146

Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg/d
Number of subjects: 331

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study: 20192280

Group type: EXPERIMENTAL
Intervention: Aliskiren 75 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Aliskiren 600 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 18534325

Group type: EXPERIMENTAL
Intervention: Aromatic essential oil massage (1% Zingiber officinale and 0.5% Citrus sinesis)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo control (olive oil massage)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (no massage)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Aromatic essential oil massage
Number of subjects: 59

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 59